Manuscript Number : IJSRSET1624177
In SITU Gelling System as a Vaccine Carrier
Authors(4) :-Chandra HS, Basant Malik, Goutam Rath, Amit K. Goyal
The delivery of protein and peptides remain challenging task for the researchers in order to maintain integrity and stability of such molecules. Therefore, during formulation development phase it passes through various stress and loss their integrity due to configuration change. Thus, the quality of vaccine adjuvant plays a major role in addition to some other factors. Therefore, the adjuvant of formulation must satisfy compatibility issues apart from degree of immune stimulation. In this paper we are describing aluminum salt as adjuvant which is widely used in commercial available vaccine formulations. Despite immunomodulatory activity it has a lot of drawbacks viz. it is attractive but weak adjuvants, induces IgE production, allergenicity and neurotoxicity. In children it also causes azotemia and severe osteomalacia intoxication devoid of renal dialysis but it is only used in parenteral, and not for mucosal vaccination. In situ gelling system is most widely studied carrier system having characteristic of depot formation by different principle same as aluminum salt. The depot system is reported by various scientists for vaccine delivery and suggesting that it is good carrier for such types of sensitive material. In situ gelling system having various advantages viz. ease of administration and reduced frequency of administration, comfort and improved patient compliance. The material used for in situ gelling also provides lot of reward like biodegradable in nature, formulation stability, and particle size uniformity, sustained, prolonged and controlled release from depot, and biocompatibility characteristics. Those drugs which are sensitive to pH and enzymatic degradations it maintained potency of the drug and provides high interaction with tissues and biological fluids. Therefore, main advantage of it is that we can achieve mucosal as well as systemic immune response by administering antigen via. mucosal and non-mucosal sites. Thus, the use of in situ gel as vaccine adjuvant could be prevents infectious disease associated with pathogens.
Chandra HS
In-situ Gel, Depot System, Vaccine Adjuvant, Depot Forming Polymers
Publication Details
Published in :
Volume 2 | Issue 4 | July-August 2016 Article Preview
Panacea Biotec Limited, Vaccine Formulation Plant, Baddi, Himachal Pradesh, India
Basant Malik
Panacea Biotec Limited, Lalru, Punjab, India
Goutam Rath
Nanomedicine Research Centre, Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
Amit K. Goyal
Nanomedicine Research Centre, Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
Date of Publication :
2016-08-30
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Page(s) :
801-814
Manuscript Number :
IJSRSET1624177
Publisher : Technoscience Academy
Journal URL :
https://ijsrset.com/IJSRSET1624177